AU7263300A - Opaminergic neuronal survival-promoting factors and uses thereof - Google Patents

Opaminergic neuronal survival-promoting factors and uses thereof

Info

Publication number
AU7263300A
AU7263300A AU72633/00A AU7263300A AU7263300A AU 7263300 A AU7263300 A AU 7263300A AU 72633/00 A AU72633/00 A AU 72633/00A AU 7263300 A AU7263300 A AU 7263300A AU 7263300 A AU7263300 A AU 7263300A
Authority
AU
Australia
Prior art keywords
opaminergic
neuronal survival
promoting factors
promoting
factors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU72633/00A
Inventor
John Commissiong
Andrei A. Raibekas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEUROTROPHIC BIOSCIENCE Inc
Original Assignee
NEUROTROPHIC BIOSCIENCE Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NEUROTROPHIC BIOSCIENCE Inc filed Critical NEUROTROPHIC BIOSCIENCE Inc
Publication of AU7263300A publication Critical patent/AU7263300A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0618Cells of the nervous system
    • C12N5/0619Neurons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/08Coculture with; Conditioned medium produced by cells of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU72633/00A 1999-09-16 2000-09-18 Opaminergic neuronal survival-promoting factors and uses thereof Abandoned AU7263300A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15466899P 1999-09-16 1999-09-16
US60/154668 1999-09-16
PCT/CA2000/001049 WO2001019851A2 (en) 1999-09-16 2000-09-18 Opaminergic neuronal survival-promoting factors and uses thereof

Publications (1)

Publication Number Publication Date
AU7263300A true AU7263300A (en) 2001-04-17

Family

ID=22552259

Family Applications (1)

Application Number Title Priority Date Filing Date
AU72633/00A Abandoned AU7263300A (en) 1999-09-16 2000-09-18 Opaminergic neuronal survival-promoting factors and uses thereof

Country Status (6)

Country Link
EP (1) EP1220681A2 (en)
JP (1) JP2003511352A (en)
AU (1) AU7263300A (en)
CA (1) CA2383076A1 (en)
MX (1) MXPA02002765A (en)
WO (1) WO2001019851A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2403804A1 (en) * 2000-03-21 2001-09-27 Curagen Corporation Vegf-modulated genes and methods employing them
JP2004528835A (en) * 2001-03-20 2004-09-24 プレサイエント・ニューロファーマ・インコーポレイテッド Dopaminergic neuron survival promoting factor and its use
US7452969B2 (en) 2002-08-30 2008-11-18 Licentia Ltd Neurotrophic factor protein and uses thereof
WO2005005471A2 (en) 2003-07-11 2005-01-20 Develogen Aktiengesellschaft Use of dg153 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
PL1969003T3 (en) 2005-12-14 2011-05-31 Herantis Pharma Plc Uses of a NEUROTROPHIC FACTOR PROTEIN
FI20080326A0 (en) 2008-04-30 2008-04-30 Licentia Oy Neurotrophic factor MANF and its uses
GB0908934D0 (en) * 2009-05-26 2009-07-01 Univ The West Of Scotland Differentiation medium
WO2015149005A1 (en) * 2014-03-28 2015-10-01 Buck Institute For Research On Aging Methods and compositions for modulating the immune system

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1219839B (en) * 1988-02-08 1990-05-24 Fidia Farmaceutici PURIFICATION, CHARACTERIZATION AND APPLICATION OF A NEURONOTROPHIC FACTOR DERIVED FROM NAMMIFEROUS BRAIN
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
CA2148138C (en) * 1992-10-28 2002-01-08 Samuel Weiss Biological factors and neural stem cells
WO1996033731A1 (en) * 1995-04-26 1996-10-31 Regeneron Pharmaceuticals, Inc. Methods of using neurotrophic factors to enhance neuronal grafts
US6222022B1 (en) * 1996-03-14 2001-04-24 Washington University Persephin and related growth factors

Also Published As

Publication number Publication date
JP2003511352A (en) 2003-03-25
EP1220681A2 (en) 2002-07-10
WO2001019851A2 (en) 2001-03-22
WO2001019851A3 (en) 2001-09-20
MXPA02002765A (en) 2005-09-08
CA2383076A1 (en) 2001-03-22

Similar Documents

Publication Publication Date Title
AU4208799A (en) Interleukins-21 and 22
AU6241698A (en) Tace-like and matrilysin-like polypeptides
AU4161899A (en) Radiotherapeutical device and use thereof
AU7687298A (en) Dihydropyrimidines and uses thereof
AU9781998A (en) Huchordin and uses thereof
AU1540001A (en) Fluorene-perylene copolymers and uses thereof
AU7612000A (en) Mono- and bis-indolylquinones and prophylactic and therapeutic uses thereof
AU3753599A (en) Micro-compartmentalization device and uses thereof
AU4198299A (en) Compounds and uses thereof
AU6636598A (en) Novel 3,4-dialkoxyphenyl derivatives and the use thereof
AU7073800A (en) Novel plexins and uses thereof
HUP0001603A3 (en) Cycloalkylalkanecarboxamides and the production and use thereof
AU2841801A (en) Triazolotriazinones and the use thereof
AU2418499A (en) Org-5222 in the treatment of depression
AU9469098A (en) Locking device
AU4776800A (en) Acetylcholinesterase-derived peptides and uses thereof
AU7263300A (en) Opaminergic neuronal survival-promoting factors and uses thereof
AU8695298A (en) Compounds and uses thereof
AU8486098A (en) Waterproof connector and waterproofing-housing member used in the same
AU6277699A (en) Guarantee 20
AU2399601A (en) Novel tachykinin-like polypeptides and use thereof
AU4629399A (en) Substituted piperazones and their therapeutic uses
AU5979300A (en) Angiopoietin-6 and uses thereof
AU2669201A (en) Taccalonolides and their use
AU3086200A (en) Eyesight-correction and/or eye-training device

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase